Avoro Capital Advisors LLC
Q2 2022 13F-HR Holdings
Net value change ($000)
-416,997
(-7.6%)
New positions
1
Sold out positions
4
Turnover %
2.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| UTHR | 156,239 | 28.7% |
| FOLD | 93,697 | 48.3% |
| ARGX | 83,779 | 21.2% |
| Seagen Inc. | 80,408 | 42.4% |
| BCRX | 38,282 | 125.6% |
| BMRN | 38,146 | 16.3% |
| RARE | 28,042 | 167.9% |
| KURA | 10,800 | 14.0% |
| SRPT | 9,208 | 3.8% |
| Mersana Therapeutics, Inc. | 7,749 | 28.6% |
Top Reduces (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | -285,065 | -41.7% |
| XBI | -207,291 | -75.6% |
| Mirati Therapeutics, Inc. | -65,213 | -14.9% |
| ACAD | -55,101 | -100.0% |
| IVERIC bio, Inc. | -53,524 | -43.9% |
| IOVA | -50,142 | -33.0% |
| ASND | -46,708 | -18.1% |
| APLS | -36,773 | -7.7% |
| MDGL | -29,946 | -21.4% |
| PRAX | -21,952 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|